User menu

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.

Bibliographic reference Devlin, Nancy ; Herdman, Michael ; Pavesi, Marco ; Phung, De ; Naidoo, Shevani ; et. al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.. In: Health and Quality of Life Outcomes, Vol. 15, no.1, p. 130-138 (2017)
Permanent URL http://hdl.handle.net/2078.1/185758
  1. Sandblom G, Carlsson P, Sennfält K, Varenhorst E, A population-based study of pain and quality of life during the year before death in men with prostate cancer, 10.1038/sj.bjc.6601654
  2. Sullivan Patrick W., Mulani Parvez M., Fishman Mayer, Sleep Darryl, Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer, 10.1007/s11136-006-9156-2
  3. Payne Heather, Pearcy Richard, Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective, 10.1016/j.jomh.2011.11.002
  4. Merseburger A. S., Bellmunt J., Jenkins C., Parker C., Fitzpatrick J. M., , Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer, 10.1634/theoncologist.2012-0478
  5. Suzman Daniel L., Antonarakis Emmanuel S., Castration-resistant prostate cancer: latest evidence and therapeutic implications, 10.1177/1758834014529176
  6. Scher Howard I., Halabi Susan, Tannock Ian, Morris Michael, Sternberg Cora N., Carducci Michael A., Eisenberger Mario A., Higano Celestia, Bubley Glenn J., Dreicer Robert, Petrylak Daniel, Kantoff Philip, Basch Ethan, Kelly William Kevin, Figg William D., Small Eric J., Beer Tomasz M., Wilding George, Martin Alison, Hussain Maha, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, 10.1200/jco.2007.12.4487
  7. Esper Peg, Mo Fei, Chodak Gerald, Sinner Michael, Cella David, Pienta Kenneth J., Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument, 10.1016/s0090-4295(97)00459-7
  8. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., Haes J. C. J. M. d., Kaasa S., Klee M., Osoba D., Razavi D., Rofe P. B., Schraub S., Sneeuw K., Sullivan M., Takeda F., The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, 10.1093/jnci/85.5.365
  9. EuroQol - a new facility for the measurement of health-related quality of life, 10.1016/0168-8510(90)90421-9
  10. Rabin Rosalind, Charro Frank de, EQ-SD: a measure of health status from the EuroQol Group, 10.3109/07853890109002087
  11. Tran C., Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., Wongvipat J., Smith-Jones P. M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C. D., Higano C. S., Beer T. M., Hung D. T., Scher H. I., Jung M. E., Sawyers C. L., Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer, 10.1126/science.1168175
  12. Hu Rong, Denmeade Samuel R, Luo Jun, Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer, 10.1586/eem.10.49
  13. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  14. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  15. Loriot Yohann, Miller Kurt, Sternberg Cora N, Fizazi Karim, De Bono Johann S, Chowdhury Simon, Higano Celestia S, Noonberg Sarah, Holmstrom Stefan, Mansbach Harry, Perabo Frank G, Phung De, Ivanescu Cristina, Skaltsa Konstantina, Beer Tomasz M, Tombal Bertrand, Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial, 10.1016/s1470-2045(15)70113-0
  16. Fizazi Karim, Scher Howard I, Miller Kurt, Basch Ethan, Sternberg Cora N, Cella David, Forer David, Hirmand Mohammad, de Bono Johann S, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, 10.1016/s1470-2045(14)70303-1
  17. Devlin Nancy J., Parkin David, Browne John, Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data, 10.1002/hec.1608
  18. EuroQol 2015. EQ-5D-3L User Guide. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.pdf . Accessed 13 Jan 2016.
  19. Pickard A Simon, Neary Maureen P, Cella David, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, 10.1186/1477-7525-5-70
  20. Dolan Paul, Modeling Valuations for EuroQol Health States : , 10.1097/00005650-199711000-00002
  21. Sullivan Patrick W., Nelson Joel B., Mulani Parvez M., Sleep Darryl, Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer, 10.1007/s11136-006-0003-2
  22. Cella D., Ivanescu C., Holmstrom S., Bui C. N., Spalding J., Fizazi K., Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial, 10.1093/annonc/mdu510
  23. Basch Ethan, Autio Karen, Ryan Charles J, Mulders Peter, Shore Neal, Kheoh Thian, Fizazi Karim, Logothetis Christopher J, Rathkopf Dana, Smith Matthew R, Mainwaring Paul N, Hao Yanni, Griffin Thomas, Li Susan, Meyers Michael L, Molina Arturo, Cleeland Charles, Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial, 10.1016/s1470-2045(13)70424-8
  24. Gater Adam, Abetz-Webb Linda, Battersby Clare, Parasuraman Bhash, McIntosh Stuart, Nathan Faith, Piault Elisabeth C, Pain in castration-resistant prostate cancer with bone metastases: a qualitative study, 10.1186/1477-7525-9-88
  25. Armstrong Andrew J., Garrett-Mayer Elizabeth, Ou Yang Yi-Chun, Carducci Michael A., Tannock Ian, de Wit Ronald, Eisenberger Mario, Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer, 10.1200/jco.2007.11.4769
  26. Halabi Susan, Vogelzang Nicholas J., Kornblith Alice B., Ou San-San, Kantoff Philip W., Dawson Nancy A., Small Eric J., Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer, 10.1200/jco.2007.15.0367
  27. Deandrea S., Montanari M., Moja L., Apolone G., Prevalence of undertreatment in cancer pain. A review of published literature, 10.1093/annonc/mdn419
  28. Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco M T, Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group, 10.1038/sj.bjc.6605053
  29. Watts Sam, Leydon Geraldine, Birch Brian, Prescott Philip, Lai Lily, Eardley Susan, Lewith George, Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates, 10.1136/bmjopen-2013-003901
  30. Gerrits Marloes M.J.G., van Marwijk Harm W.J., van Oppen Patricia, van der Horst Henriëtte, Penninx Brenda W.J.H., Longitudinal association between pain, and depression and anxiety over four years, 10.1016/j.jpsychores.2014.10.011
  31. Ko Hae Jin, Seo Se Jung, Youn Chang Ho, Kim Hyo Min, Chung Seung Eun, The Association between Pain and Depression, Anxiety, and Cognitive Function among Advanced Cancer Patients in the Hospice Ward, 10.4082/kjfm.2013.34.5.347
  32. Skaltsa Konstantina, Longworth Louise, Ivanescu Cristina, Phung De, Holmstrom Stefan, Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer, 10.1016/j.jval.2013.12.005
  33. Wolff J.M., Donatz V., Klier J., Erhardt W., Dass R.N., Geiges G., PCN120 Quality of Life Among German Patients With Metastatic Castration-Resistant Prostate Cancer, 10.1016/j.jval.2012.08.2160
  34. Wu Eric Q., Mulani Parvez, Farrell Max H., Sleep Darryl, Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients, 10.1111/j.1524-4733.2007.00195.x
  35. Feng Yan, Devlin Nancy, Herdman Mike, Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?, 10.1186/s12955-015-0356-8